NPM1 mediated up – regulation of CXCR4 might drive bortezomib resistance in multiple Myeloma
In conclusion, NPM1 might causes BTZ resistance via up-regulating CXCR4 expression in MM and could be served as both a new prognostic biomarker and a promising therapeutic target.
Authors
- Yuye Shi (ORCID: https://orcid.org/0000-0002-6853-3386)
- Tao Hong (ORCID: https://orcid.org/0000-0002-2693-8991)
- Tingting Ji (ORCID: https://orcid.org/0000-0002-1736-6856)
- Yunjie Li (ORCID: https://orcid.org/0000-0002-4464-1470)
- Jingjing Ma (ORCID: https://orcid.org/0000-0003-3944-9086)
- Liang Yu (ORCID: https://orcid.org/0009-0007-3922-3454)
- Yuan Deng (ORCID: https://orcid.org/0000-0002-9677-4793)
- Chunling Wang (ORCID: https://orcid.org/0000-0001-8239-2754)
Institutions
- Xuzhou Medical College (CN)
- Huaian First People’s Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Hematology
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1080/16078454.2025.2565956
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00